Quantcast

Latest Docetaxel Stories

2014-09-10 16:26:51

Approval based on improved overall survival, delayed time to radiographic progression and an overall positive benefit-risk profile TOKYO and SAN FRANCISCO, Sept. 10, 2014 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc. (Nasdaq: MDVN) announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for the use of XTANDI(®) (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC). This new approved...

2014-08-21 16:24:50

ENSPIRIT Trial to Continue as Planned Following Completion of the First of Two Interim Futility Analyses BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 21, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC), is continuing as planned per the recommendation of the Independent Data Monitoring Committee (IDMC) based upon completion of the...

2014-08-06 12:29:18

The Majority of Surveyed Non-Prescribers Anticipate Prescribing Xofigo Within the Next Six Months, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug. 6, 2014 /PRNewswire/ -- Decision Resources Group finds that at one year post-launch in the United States, over two thirds of surveyed U.S. medical oncologists have prescribed Bayer HealthCare's alpha-emitting radiopharmaceutical Xofigo. The majority of current non-prescribers indicated that they expect to prescribe...

2014-06-24 23:13:50

On June 20, the FDA issued a warning that Docetaxel may cause intoxication. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. San Diego, CA (PRWEB) June 24, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on Docetaxel. The FDA issued a safety communication on June 20, warning that Docetaxel may cause patients to experience...

2014-06-02 20:22:44

-- REVEL Data Published in The Lancet, Presented at Annual ASCO Meeting -- CHICAGO, June 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from REVEL, a global Phase III study of CYRAMZA((TM)) (ramucirumab) in combination with chemotherapy in patients with second-line non-small cell lung cancer (NSCLC). Data from the trial were published today in The Lancet and also presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract...

2014-06-01 08:20:11

-Study appears in June 1 online edition- NORTHBROOK, Ill. and SAN FRANCISCO, JUNE 1, 2014 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc. (Nasdaq: MDVN) today announced the online publication in the New England Journal of Medicine of the results from the Phase 3 PREVAIL trial, an international, randomized, double-blind, placebo-controlled clinical study of enzalutamide. The study evaluated the benefit...

2014-05-29 10:42:58

University of Texas M. D. Anderson Cancer Center Oncologists now have a new understanding of the toxicity levels of specific chemotherapy regimens used for women with early stage breast cancer, according to research from The University of Texas MD Anderson Cancer Center. The retrospective study, published in the Journal of Clinical Oncology, used large population-based data to compare the risk of hospitalization for six common chemotherapy regimens. Reasons for hospitalization included...

2014-05-06 08:33:30

TOKYO and SAN FRANCISCO, May 6, 2014 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) and Medivation Inc. (NASDAQ: MDVN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) to extend the indication for XTANDI® (enzalutamide) capsules for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. This sNDA application was granted Priority Review...

2014-04-30 16:30:20

Conference call to be held on Wednesday, April 30, 2014 at 4:30 p.m. Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, April 30, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and anticipated near-term milestones and announced first quarter 2014 financial results. Clinical Developments and Anticipated Near-term Milestones -- Custirsen -- Top-line survival results announced on April 28, 2014...

2014-04-28 08:31:20

BOTHELL, Wash. and VANCOUVER, British Columbia, April 28, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced results from the Phase 3 SYNERGY trial. Top-line survival results indicate that the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the primary endpoint of a statistically significant improvement in overall survival in men with metastatic castrate-resistant prostate cancer (CRPC), compared to...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'